The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) - New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability

Fiammetta Cosci*, Guy Chouinard, Virginie-Anne Chouinard, Giovanni Andrea Fava

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Aim. A wide range of clinical phenomena have been reported with dose reduction or drug discontinuation of Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs). In 2015, a new classification of SSRIs/ SNRIs withdrawal (i.e., new withdrawal symptoms, rebound symptoms withdrawal, persistent post-withdrawal disorders) was outlined on the basis of the literature and clinical observations. A semistructured clinical interview, the Diagnostic clinical Interview for Drug Withdrawal 1-New Symptoms of SSRI and SNRI (DID-W1), was developed for identifying and differentiating such syndromes. Its inter-rater reliability has been tested. Methods. Seventeen consecutive outpatients with a history of SSRI or SNRI dose reduction or discontinuation were assessed independently by 2 clinicians at different times during the same day. Percent agreement, Cohen's kappa, and the squared correlation coefficient were used to measure inter-rater reliability. Results. The percent agreement for the whole interview was 97.06%, the Cohen's kappa 0.85 (95% CI of 0.61-1.08), the squared correlation coefficient 0.72. Discussion and conclusions. The kappa values indicated excellent inter-rater agreement. Validity evaluation and comparison with other instruments need to be performed. The DID-W1 may help diagnosing the clinical phenomena related to SSRI and SNRI discontinuation, their differentiation from relapse, and the potential iatrogenic origin of psychiatric symptoms in clinical practice.
Original languageEnglish
Pages (from-to)95-99
Number of pages5
JournalRivista Di Psichiatria
Volume53
Issue number2
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • withdrawal
  • selective serotonin reuptake inhibitor
  • serotonin norepinephrine reuptake inhibitor
  • interview
  • reliability
  • iatrogenic comorbidity
  • DISCONTINUATION SYNDROME
  • ANTIDEPRESSANT DRUGS
  • IATROGENIC-COMORBIDITY
  • PANIC DISORDER
  • SCALE
  • PHARMACOPSYCHOLOGY
  • DEPRESSION
  • PAROXETINE
  • PSYCHOSIS
  • SAFETY

Cite this